Marco Antonio Stephano has a degree in Veterinary Medicine from the Federal Rural University of Rio de Janeiro. Master in Pharmacology from the State University of Campinas and a Ph.D. in Biochemical-Pharmaceutical Technology from the University of São Paulo. He was a Scientific Researcher at the Butantan Institute in the area of ??bioprocesses, reaching the Director of Quality Assurance position in 2004. In 2007 he joined the Department of Biochemical-Pharmaceutical Technology at the Faculty of Pharmaceutical Sciences of the University of São Paulo, leading research in immunobiologicals (vaccines) and biopharmaceuticals (cytokines and antibodies). He worked at the Brazilian Pharmacopoeia in ??biological and biotechnological products with ANVISA and the National Council for the Control of Animal Experimentation (CONCEA). He has been a member of the Brazilian Academy of Pharmaceutical Sciences since 2013, holding chair nº17. In the same year, he served on the scientific committee of the Institute of Medicine at the National Academies of Science in Washington on studies of counterfeit drugs. He currently participates in projects related to vaccine development for COVID-19, rabies in pets, and production of biopharmaceuticals in cell-free protein expression systems.